Key clinical point: Updated trial results have revealed durable responses with venetoclax and ibrutinib in patients with mantle cell lymphoma, allowing some patients to stop treatment.

Major finding: Five patients were able to stop treatment after achieving minimal residual disease-negative complete responses. Four of these patients remain in complete response at up to 18 months off treatment, but one patient progressed and died.

Study details: A phase 2 trial of 23 patients with relapsed/refractory mantle cell lymphoma and 1 patient with untreated disease.

Disclosures: The investigator-initiated trial was funded by Janssen and Abbvie. Dr. Handunnetti reported relationships with Abbvie and Gilead.